Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 442

1.

Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.

Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, Sun JY, Wang TT, Xie J, He HR, Xing JF, Lu J, Dong YL.

Asian Pac J Cancer Prev. 2013;14(10):6135-40.

2.

Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.

Wang C, Guo LB, Ma JY, Li YM, Liu HM.

Int J Oncol. 2013 Nov;43(5):1607-17. doi: 10.3892/ijo.2013.2083.

PMID:
24002547
3.

Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.

Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.

Life Sci. 2008 Nov 21;83(21-22):700-8. doi: 10.1016/j.lfs.2008.09.009.

PMID:
18845169
4.
5.

Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.

Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.

Cancer Chemother Pharmacol. 2006 Nov;58(5):640-53.

PMID:
16544145
6.
7.

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y.

Breast Cancer Res. 2001;3(4):253-63.

8.

Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.

Li WJ, Zhong SL, Wu YJ, Xu WD, Xu JJ, Tang JH, Zhao JH.

Mol Biol Rep. 2013 Nov;40(11):6143-50.

PMID:
24078162
9.

In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.

Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H.

J Cancer Res Clin Oncol. 2004 Mar;130(3):178-86.

PMID:
14655049
10.

ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection.

Ying W, Wang S, Shi J, Sun Y.

Med Oncol. 2012 Jun;29(2):495-502. doi: 10.1007/s12032-011-9889-9.

PMID:
21399998
11.

Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.

Tong L, Chen W, Wu J, Li H.

Anticancer Drugs. 2014 Mar;25(3):244-54. doi: 10.1097/CAD.0000000000000047.

PMID:
24275314
12.

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.

Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT.

Breast Cancer Res. 2009;11(1):R12. doi: 10.1186/bcr2231.

13.

ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.

Mao J, Song B, Shi Y, Wang B, Fan S, Yu X, Tang J, Li L.

Int J Biochem Cell Biol. 2013 Jun;45(6):1064-73. doi: 10.1016/j.biocel.2013.02.022.

PMID:
23500524
14.

Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2.

Zhu B, Liu GT, Zhao YM, Wu RS, Strada SJ.

Cancer Biol Ther. 2006 May;5(5):536-43.

PMID:
16627975
15.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

16.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1.

PMID:
20838997
17.

[Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].

Liu Q, Liu XJ, Chen YJ, Wang J.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 May;42(3):326-30, 357. Chinese.

PMID:
21826992
18.

The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.

Poma P, Notarbartolo M, Labbozzetta M, Maurici A, Carina V, Alaimo A, Rizzi M, Simoni D, D'Alessandro N.

Int J Mol Med. 2007 Sep;20(3):329-35.

PMID:
17671737
19.

Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.

Wang NN, Zhao LJ, Wu LN, He MF, Qu JW, Zhao YB, Zhao WZ, Li JS, Wang JH.

Asian Pac J Cancer Prev. 2013;14(9):4983-8.

20.

Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.

Jin J, Wang FP, Wei H, Liu G.

Cancer Chemother Pharmacol. 2005 Feb;55(2):179-88.

PMID:
15378274
Items per page

Supplemental Content

Support Center